Abstract: A virtual machine provisioning method according to an embodiment includes a provisioning module that creates a virtual machine image template including only an operating system image and a system file image, a virtual machine management module that extracts the OS image of the virtual machine image template according to a virtual machine creation command from a user, to load the OS image into a memory allocated a virtual machine, and execute the OS image, and an interface module that extracts a system file image of the virtual machine image template according to the virtual machine creation command to build a root file system for the virtual machine.

Abstract: A virtual machine provisioning method according to an embodiment includes a provisioning module that creates a virtual machine image template including only an operating system image and a system file image, a virtual machine management module that extracts the OS image of the virtual machine image template according to a virtual machine creation command from a user, to load the OS image into a memory allocated a virtual machine, and execute the OS image, and an interface module that extracts a system file image of the virtual machine image template according to the virtual machine creation command to build a root file system for the virtual machine.

Abstract: The present invention relates to a pharmaceutical composition containing a G protein coupled receptor 119 (GPR119) ligand as an effective ingredient for preventing or treating non-alcoholic steatohepatitis. More particularly, it was confirmed that the GPR119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the GPR119 ligand can be useful to treat non-alcoholic steatohepatitis.

Abstract: Provided is a pharmaceutical composition for preventing or treating liver fibrosis, comprising a GPR119 ligand as an active ingredient. The composition comprising the GPR119 ligand as an active ingredient significantly inhibits the expression of collagen I, transforming growth factor ? (TGF?) and ?-smooth muscle actin (?-SMA), thereby inhibiting HSC activation, and also significantly inhibits HSC proliferation. Therefore, the composition may be effectively applied in improvement, prevention, inhibition or treatment of liver fibrosis.

Abstract: Provided is a pharmaceutical composition for preventing or treating liver fibrosis, comprising a GPR119 ligand as an active ingredient. The composition comprising the GPR119 ligand as an active ingredient significantly inhibits the expression of collagen I, transforming growth factor ? (TGF?) and ?-smooth muscle actin (?-SMA), thereby inhibiting HSC activation, and also significantly inhibits HSC proliferation.

Abstract: The present invention relates to a pharmaceutical composition containing a G protein coupled receptor 119 (GPR119) ligand as an active ingredient for preventing or treating non-alcoholic fatty liver disease. More particularly, it was confirmed that the GPR119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the GPR119 ligand can be useful to treat non-alcoholic fatty liver.